Protocol Ledger

NCT03444883 · Phase III · COMPLETED

Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD

Interventional Phase III clinical trial protocol NCT03444883 sponsored by Il-Yang Pharm. Co in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-31 Enrollment: 277 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03444883
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)277 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03444883
Protocol FieldVerified Registry Value
NCT IdentifierNCT03444883
Consolidated Lead SponsorIl-Yang Pharm. Co
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment277 participants (ACTUAL)
Registered Start Date2018-10-31
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03444883
Hospital Research SiteLocationSite Profile
Seoul National University Bundang HospitalSeongnam-si, South KoreaOpen Hospital Dossier ->
Seoul National University HospitalSeoul, South KoreaOpen Hospital Dossier ->
Severance Hospital, Yonsei University Health SystemSeoul, South KoreaOpen Hospital Dossier ->
Asan Medical CenterSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI